408,058 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Bought by Ameriprise Financial Inc.

Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 408,058 shares of the company's stock, valued at approximately $649,000. Ameriprise Financial Inc. owned 0.45% of Caribou Biosciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CRBU. Ancora Advisors LLC grew its stake in Caribou Biosciences by 16.0% during the fourth quarter. Ancora Advisors LLC now owns 58,000 shares of the company's stock worth $92,000 after purchasing an additional 8,000 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Caribou Biosciences by 28.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company's stock worth $57,000 after acquiring an additional 8,008 shares during the period. MetLife Investment Management LLC lifted its position in shares of Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after buying an additional 9,148 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Caribou Biosciences by 9.2% during the 4th quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after buying an additional 13,421 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in Caribou Biosciences by 43.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock worth $74,000 after purchasing an additional 14,021 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Price Performance

Shares of CRBU traded down $0.04 during trading hours on Thursday, hitting $1.09. The stock had a trading volume of 446,435 shares, compared to its average volume of 1,410,828. The stock has a fifty day moving average price of $0.88 and a 200 day moving average price of $1.31. Caribou Biosciences, Inc. has a 12 month low of $0.66 and a 12 month high of $3.00. The firm has a market capitalization of $101.38 million, a PE ratio of -0.66 and a beta of 2.44.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The firm had revenue of $2.35 million during the quarter, compared to analyst estimates of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.